Guggenheim Capital’s Impax Laboratories, Inc. IPXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-15,117
| Closed | -$293K | – | 2782 |
|
|
2018
Q1 | $293K | Sell |
15,117
-110,246
| -88% | -$2.16M | ﹤0.01% | 2533 |
|
|
2017
Q4 | $2.09M | Sell |
125,363
-13,401
| -10% | -$246K | ﹤0.01% | 1641 |
|
|
2017
Q3 | $2.82M | Sell |
138,764
-28,704
| -17% | -$549K | 0.01% | 1425 |
|
|
2017
Q2 | $2.7M | Sell |
167,468
-14,311
| -8% | -$211K | 0.01% | 1416 |
|
|
2017
Q1 | $2.3M | Buy |
181,779
+35,851
| +25% | +$433K | 0.01% | 1559 |
|
|
2016
Q4 | $1.93M | Buy |
145,928
+4,144
| +3% | +$70.8K | 0.01% | 1709 |
|
|
2016
Q3 | $3.36M | Buy |
141,784
+8,253
| +6% | +$222K | 0.01% | 1263 |
|
|
2016
Q2 | $3.85M | Buy |
133,531
+801
| +0.6% | +$26.1K | 0.01% | 1131 |
|
|
2016
Q1 | $4.25M | Sell |
132,730
-42,827
| -24% | -$1.51M | 0.01% | 1084 |
|
|
2015
Q4 | $7.51M | Sell |
175,557
-56,044
| -24% | -$2.24M | 0.02% | 859 |
|
|
2015
Q3 | $8.15M | Buy |
231,601
+76,111
| +49% | +$3.43M | 0.03% | 831 |
|
|
2015
Q2 | $7.14M | Buy |
155,490
+53,048
| +52% | +$2.52M | 0.02% | 990 |
|
|
2015
Q1 | $4.8M | Buy |
102,442
+79,869
| +354% | +$3.18M | 0.01% | 1183 |
|
|
2014
Q4 | $715K | Buy |
+22,573
| New | +$661K | ﹤0.01% | 2377 |
|
|
2014
Q3 | – | Sell |
-701,300
| Closed | -$21M | – | 3201 |
|
|
2014
Q2 | $21M | Buy |
701,300
+690,909
| +6,649% | +$18.6M | 0.05% | 642 |
|
|
2014
Q1 | $274K | Sell |
10,391
-3,162
| -23% | -$79K | ﹤0.01% | 2773 |
|
|
2013
Q4 | $341K | Sell |
13,553
-31,021
| -70% | -$692K | ﹤0.01% | 2667 |
|
|
2013
Q3 | $914K | Buy |
44,574
+6,168
| +16% | +$127K | ﹤0.01% | 2140 |
|
|
2013
Q2 | $766K | Buy |
+38,406
| New | +$682K | ﹤0.01% | 2201 |
|
Guggenheim Capital's IPXL Position: Q2 2018 in Review
Guggenheim Capital sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 15,117 shares — an estimated $293K sold.
Guggenheim Capital first reported a position in IPXL in Q2 2013 and held it in 19 quarters. The position peaked at $21M in Q2 2014. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.
- Guggenheim Capital reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
- Guggenheim Capital sold 15,117 Impax Laboratories, Inc. shares in Q2 2018, an estimated $293K.
- Guggenheim Capital first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 19 quarters.
- Guggenheim Capital's Impax Laboratories, Inc. position peaked at $21M in Q2 2014.
- 1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.
Based on Guggenheim Capital's 13F filing for Q2 2018, filed 14 Aug 2018.